| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/14/2006 | EP1667998A2 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 06/14/2006 | EP1667997A1 Pyrimidine and pyridine derivatives useful as hmg-coa reductase inhibitors and method of preparation thereof |
| 06/14/2006 | EP1667996A1 Quinazoline derivatives |
| 06/14/2006 | EP1667994A1 Quinolone antibacterial agents |
| 06/14/2006 | EP1667990A2 New compounds |
| 06/14/2006 | EP1667989A1 Substituted isoquinolinones |
| 06/14/2006 | EP1667986A1 Dimethoxy docetaxel acetone solvate et method for the preparation thereof |
| 06/14/2006 | EP1667983A2 Pyrazole modulators of metabotropic glutamate receptors |
| 06/14/2006 | EP1667982A2 Isoquinolinone potassium channel inhibitors |
| 06/14/2006 | EP1667980A1 1,4-disubstituted isoquinoline derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases |
| 06/14/2006 | EP1667979A2 Isoquinoline potassium channel inhibitors |
| 06/14/2006 | EP1667978A2 Isoquinolinone potassium channel inhibitors |
| 06/14/2006 | EP1667977A1 Isoquinolinone potassium channel inhibitors |
| 06/14/2006 | EP1667976A1 Isoquinolinone potassium channel inhibitors |
| 06/14/2006 | EP1667975A1 A polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline |
| 06/14/2006 | EP1667973A2 Quinoline potassium channel inhibitors |
| 06/14/2006 | EP1667972A2 Diastereomers of 4-aryloxy-3-hydroxypiperidines |
| 06/14/2006 | EP1667970A1 Heterocyclic- or aryloxy, -thio 0r -amino substituted indoles-2-carboxylic acids or esters as pai-1 inhibitors |
| 06/14/2006 | EP1667966A1 N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
| 06/14/2006 | EP1667964A2 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 06/14/2006 | EP1667960A1 Meldonium salts, method of their preparation and pharmaceutical composition on their basis |
| 06/14/2006 | EP1667957A2 Amino acids with affinity for the alpha2delta-protein |
| 06/14/2006 | EP1667955A2 Cycloalkylidene compounds as modulators of the estrogen receptor |
| 06/14/2006 | EP1667770A2 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro [3a,3,2][ 2]- benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 06/14/2006 | EP1667769A2 Use of galanthamine and the derivatives thereof in the production of medicaments |
| 06/14/2006 | EP1667741A1 Cyanoacrylate monomer formulation containing diiodomethyl-p-tolylsulfone |
| 06/14/2006 | EP1667732A1 Biodegradable polyacetals for in vivo polynucleotide delivery |
| 06/14/2006 | EP1667731A1 Bispecific oligonucleotide for the treatment of cns malignancies |
| 06/14/2006 | EP1667728A1 Intravascular delivery of non-viral nucleic acid |
| 06/14/2006 | EP1667727A2 Polyamine-metal chelator conjugates |
| 06/14/2006 | EP1667723A1 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| 06/14/2006 | EP1667722A1 Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors |
| 06/14/2006 | EP1667720A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 06/14/2006 | EP1667719A1 Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| 06/14/2006 | EP1667710A2 Means and methods for the recruitment and identification of stem cells |
| 06/14/2006 | EP1667705A1 Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia |
| 06/14/2006 | EP1667704A1 Multiple-arm peptide compounds, methods of manufacture and use in therapy |
| 06/14/2006 | EP1667697A2 Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium. |
| 06/14/2006 | EP1667695A2 Oligonucleotides targeting prion diseases |
| 06/14/2006 | EP1667694A2 Tlr7 ligands for the treatment of hepatitis c |
| 06/14/2006 | EP1667693A1 Compositions and methods of using lamellar bodies for therapeutic purposes |
| 06/14/2006 | EP1667692A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| 06/14/2006 | EP1667691A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
| 06/14/2006 | EP1667690A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis |
| 06/14/2006 | EP1667689A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| 06/14/2006 | EP1667688A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia |
| 06/14/2006 | EP1667687A1 Pulmonary disease treatment |
| 06/14/2006 | EP1667686A1 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
| 06/14/2006 | EP1667684A1 Use of chk1 inhibitors to control cell proliferation |
| 06/14/2006 | EP1667683A2 Quinoline potassium channel inhibitors |
| 06/14/2006 | EP1667682A2 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 06/14/2006 | EP1667681A1 A novel transmucosal delivery system |
| 06/14/2006 | EP1667680A2 Combination methods of treating cancer |
| 06/14/2006 | EP1667678A1 Animal feed composition |
| 06/14/2006 | EP1667677A1 Composition for treating inflammatory bowel disease |
| 06/14/2006 | EP1667675A1 Entry inhibitors of the hiv virus |
| 06/14/2006 | EP1667674A2 A method of healing skin wounds in mammals and a composition therefor |
| 06/14/2006 | EP1667673A1 Alpha-linolenic acid and alpha-linolenic acid-containing vegetable oils used for combating diabetes |
| 06/14/2006 | EP1667672A1 Method for preventing and/or treating neurodegenerative diseases |
| 06/14/2006 | EP1667671A1 Enhanced method of treatment of growth disorders |
| 06/14/2006 | EP1667670A1 4-(1h-indol-3-yl-methylideneaminoxy-propoxy)-benzoic acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairement of the fibrinolytic system and of thrombisis |
| 06/14/2006 | EP1667668A1 Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
| 06/14/2006 | EP1667666A1 Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
| 06/14/2006 | EP1667663A1 Osmotic dosage forms for controlled delivery of alprazolam |
| 06/14/2006 | EP1667661A1 Extended release formulation of beta-lactam antibiotics |
| 06/14/2006 | EP1667660A2 Pantoprazole multiparticulate formulations |
| 06/14/2006 | EP1667657A1 Topical aerosol foams |
| 06/14/2006 | EP1667655A1 New use, pharmaceutical preparations as well as a process for their production |
| 06/14/2006 | EP1667654A2 Methods for the controlled delivery of pharmacologically active compounds |
| 06/14/2006 | EP1667653A1 Dosage form for controlled release of an active agent formulation |
| 06/14/2006 | EP1667648A2 Compositions and methods for treating burns |
| 06/14/2006 | EP1667647A2 Monocyclic and bicyclic lactams as factor xa inhibitors |
| 06/14/2006 | EP1667643A2 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| 06/14/2006 | EP1667641A1 Cosmetic or dermatological preparations having a content of isoflavones and licochalcone a |
| 06/14/2006 | EP1667635A2 Sulfonylaminovalerolactams and derivatives thereof as factor xa inhibitors |
| 06/14/2006 | EP1667633A2 Polysaccharides for pulmonary delivery of active agents |
| 06/14/2006 | EP1667622A2 Water dispersible film |
| 06/14/2006 | EP1667620A2 Active body cooling with vasodilation to reduce body temperature |
| 06/14/2006 | EP1667619A1 Pharmaceutical delivery system |
| 06/14/2006 | EP1667601A2 Silver dihydrogen citrate compositions comprising a second antimicrobial agent |
| 06/14/2006 | EP1667600A2 Dura substiture and a process for producing the same |
| 06/14/2006 | EP1667524A2 Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 06/14/2006 | EP1667518A2 Gamma-tocopherol treatment for cystic fibrosis |
| 06/14/2006 | EP1587514B1 A rapid-acting pharmaceutical composition |
| 06/14/2006 | EP1578746B1 Oxazoles as mglur1 enhancer |
| 06/14/2006 | EP1567507B1 1,2,3- triazole amide derivatives as cytokine inhibitors |
| 06/14/2006 | EP1506190B1 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker |
| 06/14/2006 | EP1497292B1 Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 06/14/2006 | EP1496884B1 Association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases |
| 06/14/2006 | EP1476434B1 Pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same |
| 06/14/2006 | EP1476136B1 Pharmaceutical composition comprising n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process for preparing thereof comprising dry granulation |
| 06/14/2006 | EP1471931A4 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| 06/14/2006 | EP1446404B1 Rosiglitazone edisylates and their use as antidiabetics |
| 06/14/2006 | EP1427420B1 Use of a combination comprising 4-pyridylmethylphthalazines for cancer treatment |
| 06/14/2006 | EP1404353A4 Methods of using a hyaluronan receptor |
| 06/14/2006 | EP1399439B1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases |
| 06/14/2006 | EP1381373B1 Medical compositions for use in the treatment or prevention of a functional vitamin b12 deficienfcy |
| 06/14/2006 | EP1379650B1 Preferred segments of neural thread protein and methods of using the same |
| 06/14/2006 | EP1377577B1 Pyrrole derivates for treating cytokine mediated diseases |
| 06/14/2006 | EP1371371B1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for preventing and treating sexual disorder |